Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial.

被引：3

作者：

Cella, David

Hackshaw, Michelle D.

Vondeling, Gerard T.

Bennett, Lee

Garbinsky, Diana

Saito, Kaku

Sugihara, Masahiro

Bang, Yung-Jue

Yamaguchi, Kensei

Shitara, Kohei

机构：

[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[2] Daiichi Sankyo Inc, Basking Ridge, NJ USA

[3] Daiichi Sankyo GmbH, Munich, Germany

[4] RTI Hlth Solut, Res Triangle Pk, NC USA

[5] Daiichi Sankyo Co Ltd, Tokyo, Japan

[6] Seoul Natl Univ, Coll Med, Seoul, South Korea

[7] JFCR, Canc Inst Hosp, Tokyo, Japan

[8] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.4057

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4057

引用

页数：2